We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
Read MoreHide Full Article
Key Takeaways
Repligen posted Q3 EPS of $0.46, which topped estimates and rose from $0.43 a year ago.
Total revenues climbed 22% year over year to $189 million, driven by strong product and order growth.
RGEN raised its 2025 revenue outlook but tightened EPS guidance, which weighed on investor sentiment.
Repligen Corporation (RGEN - Free Report) reported third-quarter 2025 adjusted earnings per share of 46 cents, which beat the Zacks Consensus Estimate of 42 cents. The company had recorded adjusted earnings of 43 cents per share in the year-ago quarter.
Total revenues in the third quarter were $189 million, up 22% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 18% organically. Revenues also beat the Zacks Consensus Estimate of $181 million.
Shares of Repligen were, however, down 5.9% on Oct. 28 following the announcement of the results.
The stock has risen 5.3% so far this year compared with the industry’s rise of 10.2%.
Image Source: Zacks Investment Research
RGEN's Q3 Earnings in Detail
The company’s top line comprises product revenues and minimal royalty and other revenues.
Product revenues were $188.8 million, up almost 21.9% from the year-ago level. Royalty and other revenues amounted to $0.04 million, up almost 5.4% year over year.
Repligen records revenues from its business franchisees that can be categorized as filtration, chromatography, proteins and process analytics. Revenues from Repligen’s base business exclude COVID-related revenues and acquisition-related revenues. The company reported 18% organic non-COVID revenue growth for the third quarter.
Total orders grew more than 20% year over year, with all the franchises witnessing double-digit growth during the third quarter.
Revenues from consumables grew more than 20% while biopharma revenues were up 20% on a year-over-year basis during the third quarter, backed by strong orders. CDMO sales, too, witnessed 20% year-over-year growth across all geographies.
RGEN's Costs, Margins & Cash Position
Adjusted gross margin was 53.3%, reflecting an increase of 260 basis points year over year.
Adjusted research and development expenses totaled approximately $13 million, up 34.6% from the year-ago quarter’s level. Adjusted selling, general and administrative expenses rose around 32.7% to $60.8 million.
Adjusted operating income totaled $26.8 million, reflecting an increase of 16% year over year.
Adjusted operating margin was 14.2% in the third quarter, lower than 14.9% in the year-ago quarter.
As of Sept. 30, 2025, Repligen had cash and cash equivalents worth $749 million compared with $709 million as of June 30, 2025.
RGEN's 2025 Guidance
Owing to the solid performance of its business so far and strong orders witnessed during the third quarter, Repligen raised its revenue outlook for 2025.
The company now expects 2025 total revenues in the range of $729-$737 million, higher than the previous expectation of $715-$735 million.
Repligen now expects organic revenue growth to be in the range of 12%-13.5% compared with the earlier projection of 10.5%-13.5% for 2025.
The company, however, tightened its adjusted EPS guidance. Earnings per share are now anticipated to be between $1.65 and $1.68, compared with the prior expectation $1.65 and $1.72. This might have hurt investors' sentiments and resulted in the stock decline yesterday.
Adjusted operating income is now expected in the range of $98-$100 million compared with the previous projection of $98-$103 million.
Repligen anticipates adjusted gross margin between 52% and 53% for 2025, unchanged from the previous expectation.
The updated guidance excludes the impact of any potential or pending acquisitions in 2025 as well as foreign exchange rates.
Repligen Corporation Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 68.9%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.36 to $4.23 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.41 to $4.21. Year to date, shares of BEAM have gained 6.5%.
Beam Therapeutics’ earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 2.62%.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from $1.22 to $1.85 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.12 to $2.49. Year to date, shares of CRMD have rallied 37.4%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 34.85%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
Key Takeaways
Repligen Corporation (RGEN - Free Report) reported third-quarter 2025 adjusted earnings per share of 46 cents, which beat the Zacks Consensus Estimate of 42 cents. The company had recorded adjusted earnings of 43 cents per share in the year-ago quarter.
Total revenues in the third quarter were $189 million, up 22% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 18% organically. Revenues also beat the Zacks Consensus Estimate of $181 million.
Shares of Repligen were, however, down 5.9% on Oct. 28 following the announcement of the results.
The stock has risen 5.3% so far this year compared with the industry’s rise of 10.2%.
Image Source: Zacks Investment Research
RGEN's Q3 Earnings in Detail
The company’s top line comprises product revenues and minimal royalty and other revenues.
Product revenues were $188.8 million, up almost 21.9% from the year-ago level. Royalty and other revenues amounted to $0.04 million, up almost 5.4% year over year.
Repligen records revenues from its business franchisees that can be categorized as filtration, chromatography, proteins and process analytics. Revenues from Repligen’s base business exclude COVID-related revenues and acquisition-related revenues. The company reported 18% organic non-COVID revenue growth for the third quarter.
Total orders grew more than 20% year over year, with all the franchises witnessing double-digit growth during the third quarter.
Revenues from consumables grew more than 20% while biopharma revenues were up 20% on a year-over-year basis during the third quarter, backed by strong orders. CDMO sales, too, witnessed 20% year-over-year growth across all geographies.
RGEN's Costs, Margins & Cash Position
Adjusted gross margin was 53.3%, reflecting an increase of 260 basis points year over year.
Adjusted research and development expenses totaled approximately $13 million, up 34.6% from the year-ago quarter’s level. Adjusted selling, general and administrative expenses rose around 32.7% to $60.8 million.
Adjusted operating income totaled $26.8 million, reflecting an increase of 16% year over year.
Adjusted operating margin was 14.2% in the third quarter, lower than 14.9% in the year-ago quarter.
As of Sept. 30, 2025, Repligen had cash and cash equivalents worth $749 million compared with $709 million as of June 30, 2025.
RGEN's 2025 Guidance
Owing to the solid performance of its business so far and strong orders witnessed during the third quarter, Repligen raised its revenue outlook for 2025.
The company now expects 2025 total revenues in the range of $729-$737 million, higher than the previous expectation of $715-$735 million.
Repligen now expects organic revenue growth to be in the range of 12%-13.5% compared with the earlier projection of 10.5%-13.5% for 2025.
The company, however, tightened its adjusted EPS guidance. Earnings per share are now anticipated to be between $1.65 and $1.68, compared with the prior expectation $1.65 and $1.72. This might have hurt investors' sentiments and resulted in the stock decline yesterday.
Adjusted operating income is now expected in the range of $98-$100 million compared with the previous projection of $98-$103 million.
Repligen anticipates adjusted gross margin between 52% and 53% for 2025, unchanged from the previous expectation.
The updated guidance excludes the impact of any potential or pending acquisitions in 2025 as well as foreign exchange rates.
Repligen Corporation Price, Consensus and EPS Surprise
Repligen Corporation price-consensus-eps-surprise-chart | Repligen Corporation Quote
RGEN's Zacks Rank & Stocks to Consider
Repligen currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals (ANIP - Free Report) , Beam Therapeutics (BEAM - Free Report) and CorMedix (CRMD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $7.25 to $7.29 for 2025. During the same time, earnings per share estimates for 2026 have increased from $7.74 to $7.81. Year to date, shares of ANIP have surged 68.9%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.36 to $4.23 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.41 to $4.21. Year to date, shares of BEAM have gained 6.5%.
Beam Therapeutics’ earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average negative surprise being 2.62%.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from $1.22 to $1.85 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.12 to $2.49. Year to date, shares of CRMD have rallied 37.4%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 34.85%.